Faheema Hasan 🩸 🩺 (@faheema_hasan) 's Twitter Profile
Faheema Hasan 🩸 🩺

@faheema_hasan

ASST PROF, HEMATO-ONCOLOGY@UIMS. ➡️ Twitter only for ❤️ of Hematology #medtwitter #mmsm #sgpgi #womeninmedicine #runner #BMT #myeloma ⚕️Hemeonc 24x7 #Tamizh

ID: 190145782

calendar_today13-09-2010 05:21:10

7,7K Tweet

5,5K Takipçi

888 Takip Edilen

Faheema Hasan 🩸 🩺 (@faheema_hasan) 's Twitter Profile Photo

👉The journey of clonal plasma cells in a video #mmsm #leusm #myeloma #MedTwitter 1. Primary genetic events ie Ig H translocation/hyperdiploidy ⏭️ initiation of clonal plasma cells in post germinal centre B cells 2.MGUS 3. Smoldering myeloma 4. 🔥 ie Myeloma with CRAB features

DrSanjeev (@drsanjeev1980) 's Twitter Profile Photo

केजीएमयू कुलपति डॉक्टर सोनिया नित्यानंद को दिल्ली में राष्ट्रपति के हाथों मिला पद्मश्री सम्मान।

केजीएमयू कुलपति डॉक्टर सोनिया नित्यानंद को दिल्ली में राष्ट्रपति के हाथों मिला पद्मश्री सम्मान।
Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

Just out: Mayo Clinic mSMART Risk Stratification of Myeloma #EHA25 1/ We recommend and use same high risk cytogenetic definition as the latest IMS/IMWG paper 2/ Primary plasma cell leukemia is high risk myeloma 3/ We define Double-hit high risk myeloma msmart.org/mm-treatment-g…

Just out: Mayo Clinic mSMART Risk Stratification of Myeloma
#EHA25

1/ We recommend and use same high risk cytogenetic definition as the latest IMS/IMWG paper

2/ Primary plasma cell leukemia is high risk myeloma

3/ We define Double-hit high risk myeloma

msmart.org/mm-treatment-g…
David Steensma, MD (@davidsteensma) 's Twitter Profile Photo

With the disappointing announcement today by AbbVie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1

With the disappointing announcement today by <a href="/abbvie/">AbbVie</a> of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1
Hematology Cancer Consortium (@hcc_hemecancer) 's Twitter Profile Photo

📣 Blood cancer patients, caregivers, and clinicians—this one’s for you. Join us for the 24th Patient Support Group Meeting by HCC. We’re breaking down Myeloproliferative Neoplasms (MPN)—a lesser-known but critical blood cancer. 🧵👇

📣 Blood cancer patients, caregivers, and clinicians—this one’s for you.
Join us for the 24th Patient Support Group Meeting by HCC.
We’re breaking down Myeloproliferative Neoplasms (MPN)—a lesser-known but critical blood cancer.
🧵👇
Hematology Cancer Consortium (@hcc_hemecancer) 's Twitter Profile Photo

🎉 From Milestone to Momentum: A look back at the impactful journey of the HCC Annual Meetings! The Hematology Cancer Consortium (HCC) has hosted some of India’s most impactful meetings in blood cancer care. Let’s take a look back — and gear up for what’s coming next! 🩸👇

🎉 From Milestone to Momentum: A look back at the impactful journey of the HCC Annual Meetings!
The Hematology Cancer Consortium (HCC) has hosted some of India’s most impactful meetings in blood cancer care. Let’s take a look back — and gear up for what’s coming next! 🩸👇
Ben Derman (@bdermanmd) 's Twitter Profile Photo

Excellent guideline on how to think about kidney transplantation in patients with plasma cell disorders. - Aim for good disease control in standard-risk myeloma - Aim for MRD negativity in high-risk myeloma - Avoid IMiDs after transplant if possible - Reduce immunosuppression

Excellent guideline on how to think about kidney transplantation in patients with plasma cell disorders. 
- Aim for good disease control in standard-risk myeloma
- Aim for MRD negativity in high-risk myeloma
- Avoid IMiDs after transplant if possible
- Reduce immunosuppression
Vaishali Sanchorawala (@vsanchorawala) 's Twitter Profile Photo

Kidney transplantation in PCDs is now a real option for select patients with ESKD due to MM, AL amyloidosis, or MGRS. A multidisciplinary panel reviews evolving evidence, challenges, and opportunities in this life-changing therapy. BU Amyloidosis Center kidney-international.org/article/S0085-…

Faheema Hasan 🩸 🩺 (@faheema_hasan) 's Twitter Profile Photo

📢📢📢 Wait, what? 😮 Regular immunoglobulin therapy didn’t reduce infection-related hospitalizations in this large study. Are we giving more than what helps? 🧪 ashpublications.org/bloodadvances/… #MedTwitter #HemeTwitter #clinicalresearch #hemeonc

📢📢📢
Wait, what? 😮
Regular immunoglobulin therapy didn’t reduce infection-related hospitalizations in this large study.
Are we giving more than what helps?
🧪 ashpublications.org/bloodadvances/…
#MedTwitter #HemeTwitter #clinicalresearch #hemeonc
Arun Kumar Arunachalam (@draruncmc) 's Twitter Profile Photo

🚨 The power of spectral flow cytometry in #Immunology & #leukemia #lymphoma profiling 💪 ✅ High-dimensional, protein-level insights ✅ Rapid, single-cell resolution ✅ Outperforms RNA-seq for functional characterization (Protein ≠ mRNA 🧬. (Transcription ≠ Protein exp)

🚨 The power of spectral flow cytometry in #Immunology &amp; #leukemia #lymphoma profiling 💪
✅ High-dimensional, protein-level insights
✅ Rapid, single-cell resolution
✅ Outperforms RNA-seq for functional characterization (Protein ≠ mRNA 🧬. (Transcription ≠ Protein exp)